Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease (BRIDGE-AD2)

NCT07680335 is registered in ClinicalTrials.gov with Alzheimercentrum Amsterdam as lead sponsor.

NCT NCT07680335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07680335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease (BRIDGE-AD2)
Lead sponsor
Alzheimercentrum Amsterdam
Phase
Not applicable
Overall status
Recruiting
Start date
September 17, 2025
Completion date
June 30, 2027
Enrollment
550 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer blood biomarkers, alzheimer's disease (ad)